Clinical Trial Update: Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer [NA]

View source ↗

Summary

A clinical trial evaluating prolonged Emend (aprepitant) in combination with oxaliplatin and topotecan for previously treated ovarian cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• EMEND (aprepitant)
• OXALIPLATIN (Oxaliplatin)
• Topotecan (topotecan)

Snippet

Sponsor: NYU Langone Health | Conditions: Ovarian Cancer | NA | Status: WITHDRAWN